Hematology · Medical Literature
Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.
Abstract
Naturally occurring tumor-specific T cells derived from peripheral blood (PB) offer a clinically accessible source for adoptive immunotherapy. However, the expansion of these T cells from patients with cancer remains a challenge. We hypothesized that mimicking innate immune activation could optimally stimulate antigen-driven T-cell expansion in vitro, unlocking the therapeutic potential of PB-derived T cells. We previously developed an ex vivo culture system that selectively expands tumor antigen-activated T cells from PB mononuclear cells (PBMC), generating multiclonal effector and central memory T cells. In this hypothesis-generating study, we evaluated the therapeutic potential of MUC1-activated T cells in patients with relapsed and/or refractory multiple myeloma (r/rMM) in a phase I clinical trial (NCT05411497). MUC1 is an oncoprotein overexpressed in r/rMM. We translated our small-scale culture into GMP-compliant, large-scale manufacturing, which achieved expansion of T cells from heavily pretreated patients' PBMCs without exhaustion. Five patients were treated with escalating doses of up to 1 × 1010 T cells. Although the cell infusions were well tolerated, no objective responses occurred. One patient, who received the highest dose, has had stable disease for 2 years after infusion. This patient exhibited transient dermatitis with localized MUC1 and CD3 staining, as potential evidence of on-target, off-tumor T-cell reactivity, perhaps contributing to disease stabilization. T-cell receptor sequencing revealed the T-cell product in four of the patients' blood, which correlated with the product's degree of polyfunctionality and MUC1 reactivity. These findings demonstrate the feasibility, safety, and biological activity of PB-derived, MUC1-specific T cells as adoptive immunotherapy. Expanding tumor antigen-specific T cells for clinical use from the blood of heavily pretreated patients with cancer remains a significant hurdle. We scale up a novel culture method that integrates innate immune signals to stimulate T-cell expansion and demonstrate safety, feasibility, and a case of long-term disease stabilization upon treatment of patients with multiple myeloma in a phase I clinical trial.
Clinical relevance
Can ex vivo expanded, MUC1-antigen-activated peripheral blood T cells be safely manufactured at GMP-compliant scale and administered to heavily pretreated patients with relapsed/refractory multiple myeloma, and do they produce objective antitumor responses? __SNAPSHOT__ {"studyDesign":"Phase I dose-escalation clinical trial (hypothesis-generating)","setting":"Mayo Clinic Cancer Center (Scottsdale and Phoenix, Arizona); IRB-approved single-institution study","sampleSize":"n=5","population":"Adults with relapsed and/or refractory multiple myeloma (r/rMM), ECOG performance status 0–1, confirmed MUC1 expression on myeloma tumor cells; heavily pretreated","intervention":"Ex vivo expanded, MUC1-antigen-activated autologous peripheral blood T cells (multiclonal effector and central memory phenotype) manufactured under GMP-compliant large-scale conditions, infused at escalating doses up to 1 × 10¹⁰ cells","comparator":"Not applicable (single-arm, dose-escalation design)","primaryOutcome":"Toxicity profile, feasibility of in-house GMP manufacturing, biological activity of MUC1-activated T cells, and manufacturing success rate; maximum tolerated dose (MTD) determination","followUp":"At least 2 years for the highest-dose patient; overall follow-up duration for the full cohort not reported in the abstract","fundingSource":"Not reported"}
Key findings
Five patients with r/rMM received escalating doses of autologous MUC1-activated peripheral blood T cells, with the maximum dose reaching 1 × 10¹⁰ cells. GMP-compliant large-scale manufacturing was successfully achieved from heavily pretreated patients' PBMCs without inducing T-cell exhaustion. All infusions were well tolerated; no dose-limiting toxicities are reported in the abstract. No objective responses were observed in any of the five patients. One patient who received the highest dose achieved stable disease, which was maintained for 2 years post-infusion. No quantitative response rates, progression-free survival estimates, specific adverse event grades, confidence intervals, or p-values are reported in the abstract. NNT is not calculable from the available data.
Practice implications
This study established the technical feasibility of manufacturing MUC1-activated, non-exhausted autologous T cells from heavily pretreated r/rMM patients at GMP scale, and demonstrated an acceptable short-term safety profile for doses up to 1 × 10¹⁰ cells. It did NOT establish clinical efficacy: zero objective responses were recorded across all five treated patients. The single case of durable stable disease at the highest dose is hypothesis-generating but cannot be attributed to treatment effect in an uncontrolled, n=5 study. The findings apply only to MUC1-expressing r/rMM patients with good performance status (ECOG 0–1); patients with poor performance status, MUC1-negative disease, or adequate organ dysfunction for standard salvage regimens were not represented. The clinical importance of the manufacturing success and tolerability findings is real, but the absence of any objective response signals significant uncertainty about whether this platform has meaningful single-agent antitumor activity in this population. Practice should not change. This work provides a manufacturing proof-of-concept and safety foundation only. Only the abstract was available for review; full manufacturing data, detailed toxicity grading, pharmacokinetics, T-cell persistence, and complete response assessments are not assessable from this summary. __LIMITATIONS__ 1. Extremely small sample size (n=5) precludes any efficacy inference or dose-response characterization. 2. Single-arm design with no comparator prevents attribution of the stable disease observation to treatment. 3. No objective responses were observed, raising the question of whether the approach has clinically meaningful single-agent activity in this heavily pretreated population. 4. Abstract-only access limits assessment of full toxicity grading, T-cell persistence kinetics, trafficking to tumor sites, and immune correlates of the stable disease case. 5. Patient selection (ECOG 0–1, confirmed MUC1 expression) limits generalizability to broader r/rMM populations. 6. Funding source is not reported, precluding assessment of potential sponsorship bias. 7. The study was explicitly described as 'hypothesis-generating,' and the authors themselves do not claim efficacy. 8. Statistical significance and clinical significance are both indeterminate given the absence of a control arm and the very small n. 9. Whether the ex vivo expansion system reliably reproduces MUC1-specific T-cell enrichment across a larger and more heterogeneous patient population is unknown. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This phase I trial (n=5) demonstrated that GMP-compliant large-scale manufacturing of MUC1-activated autologous peripheral blood T cells from heavily pretreated r/rMM patients is feasible and that infusions up to 1 × 10¹⁰ cells are well tolerated. However, no objective responses were observed, and the single case of 2-year stable disease at the highest dose is insufficient to establish clinical efficacy. This platform remains a proof-of-concept and should not influence current clinical practice; larger, potentially combination-based studies are required before any conclusions about therapeutic benefit can be drawn.